Inflammatory Myopathies (IIM): Polymyositis and Dermatomyositis “WEAK MUSCLE” Diagnosis, Staging, and Step-Care Treatment Plan By 2017 EULAR/ACR probability score
On this page
1 Pathophysiology & Clinical Presentation
| Key point | Polymyositis (PM) | Dermatomyositis (DM) |
| Immune driver | CD8⁺ T-cell–mediated myofibre injury | Humoral + complement attack on endomysial vessels |
| Core symptom | Symmetric proximal muscle weakness (climbing stairs, hair-combing) | Same muscle weakness plus pathognomonic rashes |
| Cutaneous clues | — | Heliotrope eyelid rash, Gottron papules, V-sign, shawl sign, holster sign, CMVE |
2 Diagnostic Framework
Mnemonic “W-EMB(S)” – Weakness, Enzymes, Myopathic EMG, Biopsy, (Skin for DM).
| Criterion | What to check |
| A — Muscle weakness | Symmetric, proximal, ≥ 4 weeks |
| B — Muscle enzymes | CK, AST, ALT, LDH, aldolase ↑ |
| C — EMG | Fibrillation potentials, short polyphasic MUAPs |
| D — Biopsy | PM → endomysial CD8⁺ & necrosis; DM → perifascicular atrophy |
| E — Skin | Heliotrope, Gottron, CMVE, V/shawl/holster signs |
Diagnosis: PM = A–D present, no E. DM = E + ≥ 3 of A–D. Apply the 2017 EULAR/ACR probability score to label possible/probable/definite IIM; a score ≥ 7.5 (with biopsy) or ≥ 8.7 (without) = definite myositis.org.
Diving Deeper into the Core Diagnostic Criteria for Polymyositis (PM) & Dermatomyositis (DM)
3 Staging & Activity Monitoring
| Domain | Tool (+ timing) | Clinically meaningful change |
| Muscle strength | MMT-8 every visit (0–80) | Response = ≥ 20 % or ≥ 6-point gain sralab.org |
| Global disease activity | IMACS Core Set Measures → calculate ACR/EULAR Total Improvement Score (TIS) | TIS ≥ 20 = minimal, ≥ 40 = moderate, ≥ 60 = major improvement academic.oup.comniehs.nih.gov |
| Skin severity (DM) | CDASI activity score | ≤ 14 mild, 15–40 moderate, > 40 severe jaad.org |
| Permanent damage | Myositis Damage Index (MDI) yearly | Higher score = chronic / polycyclic course |
| Extra-muscular | HRCT + PFTs (ILD), echo ± RHC (PAH), age-appropriate malignancy screen (anti-TIF1-γ, NXP-2) | — |
4 Investigations – “MIOSITIS” checklist
| Letter | Order this | Purpose |
| M | MRI STIR thighs/shoulders | Localise active muscle for biopsy |
| I | Immune panel (MSA/MAA) | Phenotype & prognosis (e.g., anti-MDA-5 → RP-ILD) |
| O | Organ screen – HRCT, PFTs, echo, LFTs | Baseline & follow-up |
| S | Serum enzymes – CK etc. | Disease activity |
| I | Infection screen – HBV/HCV, HIV, IGRA | Pre-immunosuppression |
| T | Tumour search > 40 yrs | CT chest/abd/pelvis, mammogram/colonoscopy/PSA |
| I | Interval labs q 4–8 w on therapy | Response & toxicity |
| S | Strength testing (MMT-8 / dynamometer) | Objective follow-up |
5 Management – Treat-to-Target ≤ 6 months
| Step | Drug(s) & key points | Escalate when… |
| 1 High-dose steroid | Prednisone 1 mg/kg/day (max 80 mg) ± IV methyl-pred 1 g ×3 if severe dysphagia/RP-ILD | CK or strength plateaus, unable to taper < 20 mg by 3 mo |
| 2 Steroid-sparing csDMARD (start ≤ 4 wks) | Methotrexate 15–25 mg/wk or Azathioprine 2–3 mg/kg/d. ILD: Mycophenolate 1 g bid / Tacrolimus 1–3 mg bid | Persistent activity or steroid-toxicity |
| 3 IVIG 2 g/kg monthly | Rapid weakness, dysphagia, pregnancy, or refractory DM rash | Re-check after 3 cycles |
| 4 Biologic / targeted | Rituximab 1 g × 2 (RIM trial) myositis.org, Abatacept, JAK-i (Tofacitinib) for anti-MDA-5 ILD, Cyclophosphamide for severe ILD | |
| 5 Cutaneous DM adjuncts | Hydroxychloroquine 200–400 mg/d, potent topical steroids, sun-block | |
| 6 Rehab & prevention | Early physiotherapy, vitamin D + DEXA, vaccines (flu, pneumococcal, zoster, COVID-19) |
Toxicity pearls • MTX → hepatotoxicity & pneumonitis • AZA → TPMT/NUDT15-related cytopenia • Mycophenolate → cytopenia & diarrhoea • Rituximab → HBV reactivation.
6 General Doctor vs Rheumatology – who does what?
| Task | GP / Internist | Needs Rheumatologist |
| Suspicion, baseline CK, ANA, rule-out infection | ✓ | — |
| Start high-dose steroid if profound weakness or ILD | ✓ (then phone Rheum same day) | Dose-taper & DMARD plan |
| Vaccination, osteoporosis prophylaxis, BP/DM care | ✓ | — |
| Routine labs & CK q 4–8 w | ✓ (forward to Rheum) | Adjust drugs / interpret flares |
| Decisions on IVIG, biologics, cyclophosphamide | ✗ | ✓ – complex immunotherapy |
| Work-up / management of ILD, PAH, malignancy | Arrange tests | Rheum + Respiratory / Oncology |
| Refractory disease, pregnancy, juvenile cases | Stabilise & refer | Multidisciplinary care |
Bottom line: All confirmed or strongly suspected IIM patients require early Rheumatology co-management; the generalist initiates life-saving steroids, screens for comorbidities, and provides long-term preventive care.
7 High-yield Dermatomyositis Rashes
| Rash | Clinical clue | Exam mnemonic |
| Gottron papules | Violaceous papules over MCP/PIP | “Got Guitar Knuckles” |
| Heliotrope | Lilac eyelid discoloration ± oedema | “Helios = sun-purple” |
| V-sign / Shawl sign | Photodistributed chest / shoulder erythema | Letter shapes on skin |
| Holster sign | Lateral thigh erythema | “Gun-holster rash” |
| CMVE | Confluent macular violaceous erythema | Key board-style patch |
One-minute OSCE Script
- “Mrs D has symmetric proximal weakness, CK 2400 IU/L, heliotrope rash → 2017 EULAR/ACR score 9.1 = definite dermatomyositis.”
- Stage: MMT-8 54/80 (moderate), TIS baseline 0, CDASI 28 (moderate), HRCT clear.
- Order MRI thighs, myositis panel, EMG, and malignancy screen.
- Start Prednisone 1 mg/kg + Methotrexate 15 mg/wk + calcium/vit-D; refer to Rheumatology within a week; physiotherapy day 1.
- Review CK & strength at 4 weeks; add IVIG if TIS < 20.
Use “W-EMB(S)”, TIS 20-40-60, and MIOSITIS check-list to keep both patients and examiners safe.
Diving Deeper into the Core Diagnostic Criteria for Polymyositis (PM) & Dermatomyositis (DM)
Below, each element of the classic A–E framework is unpacked in detail and cross-mapped to the weightings in the 2017 EULAR/ACR probability score (the current research-grade standard).
| Criterion | What to document in practice | Key histo-/physiologic pearls | EULAR/ACR weight (with biopsy) |
|---|---|---|---|
| A — Muscle weakness | • Manual Muscle Testing (MMT-8) or dynamometry of neck-flexors, deltoids, biceps, wrist extensors, iliopsoas, gluteus maximus, quadriceps, ankle dorsiflexors. • Symmetric, proximal, ≥ 4 weeks; neck-flexors weaker than extensors; proximal legs weaker than distal. | CD8⁺ T-cell cytotoxicity in PM; perifascicular ischemia in DM cause predominantly proximal fibre loss. | • Prox UL: 0.7 • Prox LL: 0.5 • Neck-flexor < extensor: 1.6 • Prox > distal leg: 1.2 myositis.org |
| B — Muscle enzymes | Order CK, aldolase, AST, ALT, LDH at baseline and every taper decision. Typical CK peaks: • PM / DM active: > 1 000 IU (L) (may reach > 10 000). • “Amyopathic” DM: CK often normal. | CK tracks necrosis/regeneration; aldolase may rise first as CK normalises. Beware: strenuous exercise, statins and hypothyroidism also raise CK. | CK/LD/AST/ALT↑: 1.4 health.com |
| C — Electromyography | Needle EMG in ≥ 2 proximal & 1 distal muscle: • Fibrillation/positive sharp waves at rest • Short-duration (< 5 ms), low-amplitude (< 500 µV) polyphasic MUAPs • Early full recruitment with minimal effort | Reflects membrane irritability from inflammatory insult. Complex repetitive discharges & “myotonic-like” potentials bolster diagnosis. | (EMG is not scored in 2017 criteria but remains clinically invaluable) myositis.org |
| D — Muscle biopsy | Biopsy an MRI-edematous site before steroids if possible. Process fresh-frozen + formalin. | Polymyositis → Endomysial CD8⁺ T-cells & macrophages invading non-necrotic fibres with diffuse MHC-I up-regulation. autoimmunhighlights.biomedcentral.com Dermatomyositis → Perifascicular atrophy, perivascular/ perimysial CD4⁺ T-cells & B-cells, capillary C5b-9 complement deposition. academic.oup.com | • Endomysial inflam (non-invasive): 1.7 • Perivascular/perimysial inflam: 1.2 • Perifascicular atrophy: 1.9 myositis.org |
| E — Skin manifestations (DM) | Heliotrope rash (eyelids), Gottron papules/sign, V-sign, shawl sign, holster sign, Mechanics hands, periungual telangiectasia. Document photos under good light. | Skin pathology shows interface dermatitis & mucin; MxA and IFN-signature staining aid amyopathic DM Dx. | • Heliotrope: 3.2 • Gottron papule: 2.7 • Gottron sign: 3.7 myositis.org |
How the 2017 EULAR/ACR Probability Score Works
- Assign points for each variable present (table clip above).
- Sum the points.
- Convert to a probability of IIM:*Without biopsy: P = 1 / [1 + e^(6.49 – score)]With biopsy: P = 1 / [1 + e^(5.33 – score)] myositis.org
- Interpret:
- ≥ 7.5 (no biopsy ≥ 8.7) → Definite IIM (> 90 % probability)
- 5.5 – 7.4 (no biopsy 6.7 – 8.6) → Probable IIM (> 55 %)
- 5.3 – 5.4 → Possible IIM (50–55 %)
- < 5.3 (< 6.5 with biopsy) → Unlikely
Shortcut rule still acceptable in clinics: PM = A–D + absence of E | DM = E + ≥ 3 of A–D (Bohan & Peter).
Putting It Together – Sample Calculation
Patient: 46-year-old woman with proximal leg weakness (MMT 4/5), heliotrope rash, neck-flexor 3/5, CK 3500, anti-Jo-1⁺, biopsy shows perifascicular atrophy.
| Variable | Points |
| Age ≥ 40 | 2.2 |
| Prox-LL weakness | 0.5 |
| Neck-flexor weaker | 1.6 |
| CK↑ | 1.4 |
| Heliotrope | 3.2 |
| Anti-Jo-1 | 3.8 |
| Perifascicular atrophy | 1.9 |
| Total | 14.6 |
With biopsy:P = 1 / [1 + e^(5.33 – 14.6)] ≈ 0.999 → Definite DM.
Practical Tips for Each Criterion
- Weakness (A) – always test neck flexors; their relative weakness carries the biggest score (1.6 pts).
- Enzymes (B) – trend CK every 4–8 weeks; a fall > 80 % yet persistent weakness suggests steroid-induced myopathy rather than active disease.
- EMG (C) – combine with MRI (STIR) to target biopsy and avoid false-negatives.
- Biopsy (D) – take from deltoid or vastus lateralis; avoid severely atrophic muscle. Request MHC-I, CD3, C5b-9 immunostains.
- Skin (E) – photograph lesions; they may fade after steroids, hampering later scoring.
Key Take-aways
- Weightings matter: heliotrope rash (3.2 pts) or anti-Jo-1 (3.8 pts) can swing a case from “possible” to “definite” quickly.
- Biopsy deepens certainty and allows subtype classification (PM vs DM vs IBM).
- Use the web calculator (link in criteria paper) at the bedside for exact probability.
- Remember the probability concept: the criteria classify for research; clinical judgment still rules when treatment can’t wait for a biopsy.
Feel free to ask for more on biopsy techniques, MRI protocols, or management algorithms!
Comments
No comments yet. Be the first to share your thoughts.
Sign in to comment